期刊文献+

Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation 预览 被引量:1

Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation
在线阅读 免费下载
收藏 分享 导出
摘要 AIM: To compare the recurrence-free survival(RFS) and overall survival(OS) of hepatitis B virus(HBV)-positive hepatocellular carcinoma(HCC) after living donor liver transplantation(lDlT) and deceased donor liver transplantation(DDlT).METHODS: We retrospectively collected clinical data from 408 liver cancer patients from February 1999 to September 2012. We used the chi-squared test or Fisher’s exact test to analyze the characteristics of lDlT and DDlT. Kaplan-Meier analysis was used to compare the RFS and OS in HCC.RESULTS: Three hundred sixty HBV-positive patients(276 DDlT and 84 lDlT) were included in this study.The mean follow-up time was 27.1 mo(range 1.1-130.8 mo). One hundred eighty-five(51.2%) patients died during follow-up. The 1-, 3-, and 5-year RFS rates for lDlT were 85.2%, 55.7%, and 52.9%, respectively; for DDlT, the RFS rates were 73.2%, 49.1%, and 45.3%(P = 0.115). The OS rates were similar between the lDlT and DDlT recipients, with 1-, 3-, and 5-year survival rates of 81.8%, 49.5%, and 43.0% vs 69.5%, 43.0%, and 38.3%, respectively(P = 0.30). The outcomes of HCC according to the Milan criteria after lDlT and DDlT were not significantly different(for lDlT: 1-, 3-, and 5-year RFS: 94.7%, 78.7%, and 78.7% vs 89.2%, 77.5%, and 74.5%, P = 0.50; for DDlT: 86.1%, 68.8%, and 68.8% vs 80.5%, 62.2%, and 59.8% P = 0.53).CONCLUSION: The outcomes of lDlT for HCC are not worse compared to the outcomes of DDlT. lDlT does not increase tumor recurrence of HCC compared to DDlT. AIM: to compare the recurrence-free survival (RFS) and overall survival (OS) of hepatitis B virus (HBV)-positive hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT) and deceased donor liver transplantation (DDLT). METHODS: We retrospectively collected clinical data from 408 liver cancer patients from February 1999 to September 2012. We used the chi-squared test or Fisher's exact test to analyze the characteristics of LDLT and DDLT. Kaplan-Meier analysis was used to compare the RFS and OS in HCC. RESULTS: Three hundred sixty HBV-positive patients (276 DDLT and 84 LDLT) were included in this study. The mean follow-up time was 27.1 mo (range 1.1-130.8 mo). One hundred eighty-five (51.2%) patients died during follow-up. The 1-, 3-, and 5-year RFS rates for LDLT were 85.2%, 55.7%, and 52.9%, respectively; for DDLT, the RFS rates were 73.2%, 49.1%, and 45.3% (P = 0.115). The OS rates were similar between the LDLT and DDLT recipients, with 1-, 3-, and 5-year survival rates of 81.8%, 49.5%, and 43.0% vs 69.5%, 43.0%, and 38.3%, respectively (P = 0.30). The outcomes of HCC according to the Milan criteria after LDLT and DDLT were not significantly different (for LDLT: 1-, 3-, and 5-year RFS: 94.7%, 78.7%, and 78.7% vs 89.2%, 77.5%, and 74.5%, P = 0.50; for DDLT: 86.1%, 68.8%, and 68.8% vs 80.5%, 62.2%, and 59.8% P = 0.53). CONCLUSION: The outcomes of LDLT for HCC are not worse compared to the outcomes of DDLT. LDLT does not increase tumor recurrence of HCC compared to DDLT. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
作者 Guang-qin Xiao Jiu-lin Song Shu Shen Jia-yin yang Lu-nan yan Guang-qin Xiao;Jiu-lin Song;Shu Shen;Jia-yin yang;lu-nan yan;Liver Transplantation Center, West China Hospital of Sichuan University;
出处 《世界胃肠病学杂志:英文版》 SCIE CAS 2014年第31期10953-10959,共7页 World Journal of Gastroenterology
基金 National Science and Technology Major Project of China,No.2012ZX10002-016 and No.2012ZX10002017-017
关键词 HEPATOCELLULAR carcinoma LIVING DONOR Deceased DON Hepatocellular carcinoma Living donor Deceased donor Liver transplantation Hepatitis B virus
  • 相关文献

参考文献14

  • 1Li, Chuan,Wen, Tian-Fu,Yan, Lu-Nan,Li, Bo,Yang, Jia-Ying,Wang, Wen-Tao,Xu, Ming-Qing,Wei, Yong-Gang,.Outcome of hepatocellular carcinoma treated by liver transplantation:comparison of living donor and deceased donor transplantation[J].国际肝胆胰疾病杂志:英文版,2010(4):366-369. 被引量:3
  • 2Jiang, Li,Yan, Lu-Nan.Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation[J].世界胃肠病学杂志:英文版(电子版),2010(20):2468-2475. 被引量:7
  • 3Jin Li Lu-Nan Yan Jan Yang Zhe-Yu Chen Bo Li Yong Zeng Tian-Fu Wen Ji-Chun Zhao Wen-Tao Wang Jia-Yin Yang Ming-Qing Xu Yu-Kui Ma.Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients[J].世界胃肠病学杂志:英文版(电子版),2009(33):4170-4176. 被引量:9
  • 4Modified techniques for adult-to-adult living donor liver transplantation[J].国际肝胆胰疾病杂志:英文版,2006(2):173-179. 被引量:2
  • 5Min-Su Park,Kwang-Woong Lee,Suk-Won Suh,Tae You,YoungRok Choi,Hyeyoung Kim,Geun Hong,Nam-Joon Yi,Choon-Hyuck David Kwon,Jae-Won Joh,Suk-Koo Lee,Kyung-Suk Suh.Living-Donor Liver Transplantation Associated With Higher Incidence of Hepatocellular Carcinoma Recurrence Than Deceased-Donor Liver Transplantation[J].Transplantation Journal.2014(1) 被引量:2
  • 6Jianyong Lei,Lunan Yan,Wentao Wang.Comparison of the outcomes of patients who underwent deceased-donor or living-donor liver transplantation after successful downstaging therapy[J].European Journal of Gastroenterology & Hepatology.2013(11) 被引量:2
  • 7L. M. Kulik,R. A. Fisher,D. R. Rodrigo,R. S. Brown, Jr.,C. E. Freise,A. Shaked,J. E. Everhart,G. T. Everson,J. C. Hong,P. H. Hayashi,C. L. Berg,A. S. F. Lok.Outcomes of Living and Deceased Donor Liver Transplant Recipients With Hepatocellular Carcinoma: Results of the A2ALL Cohort<sup>?</sup>[J].American Journal of Transplantation.2012(11) 被引量:2
  • 8ToshimiKaido,ShinjiUemoto.Does living donation have advantages over deceased donation in liver transplantation?[J].Journal of Gastroenterology and Hepatology.2010(10) 被引量:2
  • 9Vincenzo Mazzaferro,Josep M Llovet,Rosalba Miceli,Sherrie Bhoori,Marcello Schiavo,Luigi Mariani,Tiziana Camerini,Sasan Roayaie,Myron E Schwartz,Gian Luca Grazi,René Adam,Peter Neuhaus,Mauro Salizzoni,Jordi Bruix,Alejandro Forner,Luciano De Carlis,Umberto Cillo,Andrew K Burroughs,Roberto Troisi,Massimo Rossi,Giorgio E Gerunda,Jan Lerut,Jacques Belghiti,Ilka Boin,Jean Gugenheim,Fedja Rochling,Bart Van Hoek,Pietro Majno.Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J].Lancet Oncology.2009(1) 被引量:4
  • 10S. Di Sandro,A.O. Slim,A. Giacomoni,A. Lauterio,I. Mangoni,P. Aseni,V. Pirotta,A. Aldumour,P. Mihaylov,L. De Carlis.Living Donor Liver Transplantation for Hepatocellular Carcinoma: Long-Term Results Compared With Deceased Donor Liver Transplantation[J].Transplantation Proceedings.2009(4) 被引量:2

二级参考文献73

  • 1Zhang, Jian,Zhou, Lin,Zheng, Shu-Sen,.Clinical management of hepatitis B virus infection correlated with liver transplantation[J].国际肝胆胰疾病杂志:英文版,2010(1):15-21. 被引量:2
  • 2Ran, Shun,Wen, Tian-Fu,Yan, Lu-Nan,Li, Bo,Zeng, Yong,Chen, Zhe-Yu,Zhang, Yu,Liao, Zhi-Xue,Liang, Guan-Lin,Li, Guo,Zhang, Xian-Hua,.Risks faced by donors of right lobe for living donor liver transplantation[J].国际肝胆胰疾病杂志:英文版,2009(6):581-585. 被引量:3
  • 3Pichlmayr R,Weimann A,Ringe B.Indications for liver transplantation in hepatobiliary malignancy.Hepatology 1994;20:33S-40S. 被引量:1
  • 4Mazzaferro V,Regalia E,Doci R,Andreola S,Pulvirenti A,Bozzetti F,Montalto F,Ammatuna M,Morabito A,Gennari L.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med 1996;334:693-699. 被引量:1
  • 5Figueras J,Jaurrieta E,Valls C,Benasco C,Rafecas A,Xiol X,Fabregat J,Casanovas T,Torras J,Baliellas C,Iba.ez L,Moreno P,Casais L.Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma:a comparative study.Hepatology 1997;25:1485-1489. 被引量:1
  • 6American Liver Tumor study group.A randomized prospective multi-institutional trial of orthotopic liver transplantation or partial hepatic resection with or without adjuvant chemotherapy for hepatocellular carcinoma.Investigator Booklet and protocol,1998. 被引量:1
  • 7International Union Against Cancer (UICC).TNM classification of tumors.In:Sobin LH,Wittekind HC,eds.5th ed.New York:Wiley-Liss,1997:74-77. 被引量:1
  • 8Yao FY,Ferrell L,Bass NM,Watson JJ,Bacchetti P,Venook A,Ascher NL,Roberts JP.Liver transplantation for hepatocellular carcinoma:expansion of the tumor size limits does not adversely impact survival.Hepatology 2001;33:1394-1403. 被引量:1
  • 9Marsh JW,Dvorchik I.Liver organ allocation for hepatocellular carcinoma:are we sure? Liver Transpl 2003;9:693-696. 被引量:1
  • 10Todo S,Furukawa H.Living donor liver transplantation for adult patients with hepatocellular carcinoma:experience in Japan.Ann Surg 2004;240:451-459;discussion 459-461. 被引量:1

共引文献33

同被引文献111

  • 1Toru Ishikawa.Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma[J].世界胃肠病学杂志:英文版(电子版),2013,0(47):8861-8866. 被引量:1
  • 2Zhong-Ming Tan,Bei-Cheng Sun.Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence[J].世界胃肠病学杂志:英文版(电子版),2013,0(47):8895-8901. 被引量:2
  • 3Matteo Cescon,Valentina Rosa Bertuzzo,Giorgio Ercolani,Matteo Ravaioli,Federica Odaldi,Antonio Daniele Pinna.Liver transplantation for hepatocellular carcinoma:Role of inflammatory and immunological state on recurrence and prognosis[J].世界胃肠病学杂志:英文版(电子版),2013,0(48):9174-9182. 被引量:3
  • 4K. V. Menon,A. R. Hakeem,N. D. Heaton.Meta‐analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther . 2012 (4) 被引量:8
  • 5Robert C. Grant,Lakhbir Sandhu,Peter R. Dixon,Paul D. Greig,David R. Grant,Ian D. McGilvray.Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta‐analysis[J].Clin Transplant.2012(1) 被引量:4
  • 6Austin G. Acheson,Matthew J. Brookes,Donat R. Spahn.Effects of Allogeneic Red Blood Cell Transfusions on Clinical Outcomes in Patients Undergoing Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis[J].Annals of Surgery.2012(2) 被引量:3
  • 7Manuel Rodríguez-Perálvarez,Emmanuel Tsochatzis,María Carmen Naveas,Giulia Pieri,Carmen García-Caparrós,James O’Beirne,Antonio Poyato-González,Gustavo Ferrín-Sánchez,Jose Luis Montero-álvarez,David Patch,Douglas Thorburn,Javier Brice?o,Manuel De la Mata,Andrew Kenneth Burroughs.Reduced Exposure to Calcineurin Inhibitors Early After Liver Transplantation Prevents Recurrence of Hepatocellular Carcinoma[J].Journal of Hepatology.2013 被引量:5
  • 8Shu-Sen Zheng,Xiao Xu,Jian Wu,Jun Chen,Wei-Lin Wang,Min Zhang,Ting-Bo Liang,Li-Ming Wu.Liver Transplantation for Hepatocellular Carcinoma: Hangzhou Experiences[J].Transplantation.2008(12) 被引量:7
  • 9Min-Su Park,Kwang-Woong Lee,Suk-Won Suh,Tae You,YoungRok Choi,Hyeyoung Kim,Geun Hong,Nam-Joon Yi,Choon-Hyuck David Kwon,Jae-Won Joh,Suk-Koo Lee,Kyung-Suk Suh.Living-Donor Liver Transplantation Associated With Higher Incidence of Hepatocellular Carcinoma Recurrence Than Deceased-Donor Liver Transplantation[J].Transplantation Journal.2014(1) 被引量:2
  • 10S. Di Sandro,A.O. Slim,A. Giacomoni,A. Lauterio,I. Mangoni,P. Aseni,V. Pirotta,A. Aldumour,P. Mihaylov,L. De Carlis.Living Donor Liver Transplantation for Hepatocellular Carcinoma: Long-Term Results Compared With Deceased Donor Liver Transplantation[J].Transplantation Proceedings.2009(4) 被引量:2

引证文献1

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈